Search Results

You are looking at 141 - 150 of 182 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Monique A. de Bruin, James M. Ford, and Allison W. Kurian

irradiation (this radiation was performed prior to her TP53 mutation testing). She completed a year of trastuzumab and initiated tamoxifen therapy for a planned 5-year course. She tolerated all of this therapy well. Given her diagnosis of LFS, she is

Full access

Siu-Fun Wong, Mark Bounthavong, Cham P. Nguyen, and Timothy Chen

. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer . Lancet 2005 ; 365 : 60 – 62 . 21. Chlebowski RT Geller ML . Adherence to endocrine therapy for

Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen [abstract] . J Clin Oncol 2008 ; 26 ( Suppl ): Abstract 564 . 17. Van Poznak C Hannon R Clack G . Managing cancer treatment

Full access

Rachel L. Mitchell, Cory Kosche, Kelly Burgess, Shreya Wadhwa, Lela Buckingham, Ritu Ghai, Jacob Rotmensch, Oleksandra Klapko, and Lydia Usha

-agent carboplatin, tamoxifen, and anastrozole. Because the patient had a personal history of fallopian tube carcinoma, she was a candidate for genetic testing for BRCA1 and BRCA2 mutations. Additionally, due to a family history significant for multiple

Full access

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda

. Case 1 A 66-year-old Ashkenazi Jewish woman with a past medical history of early-stage invasive ductal carcinoma of the left breast, treated definitively with surgery and adjuvant tamoxifen therapy, presented after a routine colonoscopy revealed a 1

Full access

Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh

paclitaxel. She received 4 cycles of doxorubicin at 60 mg/m 2 . She was not given adjuvant tamoxifen because data supporting its adjuvant use was not mature at that time. In the setting of bilateral breast cancer in a young woman with maternal Ashkenazi

Full access

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage

tamoxifen. All 3 patients had splenomegaly. The WBC count at presentation was 143,000/μL (66% blasts; 5% basophils) in the first patient ( Figure 1 ); 159,000/μL (36% blasts; 0%-2% basophils) in the second patient; and 96,900/μL (12% blasts; 1% basophils) in

Full access

Tilmann Bochtler, Volker Endris, Anna Reiling, Jonas Leichsenring, Michal R. Schweiger, Sebastian Klein, Fabian Stögbauer, Benjamin Goeppert, Peter Schirmacher, Alwin Krämer, and Albrecht Stenzinger

hormone receptor–positive (estrogen receptor [ER], 12/12; progesterone receptor [PR], 8/12; HER2/neu, 1+) ductal adenocarcinoma of luminal type B, which was treated with surgical resection and subsequent adjuvant tamoxifen, which is still ongoing at time

Full access

Jesse D. Troy, Carlos M. de Castro, Mary Ruth Pupa, Greg P. Samsa, Amy P. Abernethy, and Thomas W. LeBlanc

.org . 3. Zabora J BrintzenhofeSzoc K Curbow B . The prevalence of psychological distress by cancer site . Psychooncology 2001 ; 10 : 19 – 28 . 4. Partridge AH Wang PS Winer EP Avorn J . Nonadherence to adjuvant tamoxifen therapy in

Full access

Mary B. Daly, Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P. Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R. Smith, Elizabeth Swisher, and Jeffrey N. Weitzel

For example, experts have suggested that the increased risk for endometrial cancer observed in some BRCA1 or 2 mutation carriers is mainly caused by the use of tamoxifen therapy rather than the presence of a gene mutation. 51 Germline mutations